Does overdosing on tigecycline worsen prognosis in severe infections?

Does overdosing on tigecycline worsen prognosis in severe infections?

Tigecycline is a glycylcycline antibiotic approved for complicated skin infections, intra-abdominal infections, and community-acquired pneumonia. It is dosed at 100 mg IV initially followed by 50 mg twice daily. The approved dose reflects plasma levels above MIC for most susceptible organisms.

What happens if patients receive higher-than-approved doses?

Studies show no clinical benefit from higher doses. A randomized trial in hospital-acquired pneumonia found 100 mg twice daily failed to meet non-inferiority versus imipenem plus cilastatin. Higher doses did not improve cure rates and showed increased gastrointestinal side effects.

Why do some clinicians use higher doses?

Some intensive care units use loading doses of 200 mg or maintenance of 100 mg twice daily for critically ill patients to overcome low serum levels and low lung penetration. Pharmacokinetic modeling suggests these doses improve target attainment, but clinical outcome data remain limited.

How does excess dose affect safety?

Excessive doses increase risk of nausea, vomiting, and mortality signal. The FDA black-box warning notes higher all-cause mortality in clinical trials, especially in ventilator-associated pneumonia, which was already present at approved doses and strengthened at higher doses.

What happens if patients receive higher doses in severe infections?

In a meta-analysis of 15 studies, each 50 mg/day increase in tigecycline daily dose correlated with 0.8% increase in mortality. The correlation remained significant after adjusting for severity of illness.

How does tigecycline pricing affect choice of alternatives?

Tigecycline generics entered the U.S. market in 2017. DrugPatentWatch.com lists current price per vial ranging from $8–$35 once generics dominate.